Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Snapshots: new reports on biomarkers related to cardiovascular disorders

April 30, 2010

Clinical data from the evaluation of Debio-025 in HCV-infected patients disclosed

April 30, 2010

Recent data support safety and potentcy of HCV NS3 protease inhibitor ACH-1625

April 30, 2010

Erythropoietin does not show benefit in pediatric cardiac surgery

April 29, 2010

MK-5172 shows potent preclinical activity against resistance-linked HCV NS3/4a protease variants

April 29, 2010

L-Hyd4FC shows potent in vivo activity in HBV-infected mice

April 29, 2010

In vivo safety and antitumor activity of ABI-013 disclosed

April 29, 2010

Phase II data presented on pasireotide in Cushing's disease and acromegaly

April 29, 2010

Pfizer details discovery and activity of dual PI3K/mTOR inhibitor PF-04691502

April 29, 2010

Clinical data disclosed on Locteron/ribavirin vs. PEG-Intron/ribavirin in HCV genotype 1

April 29, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...